Labiotech.eu – 19/10/2016
ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest funding round of the year in Europe: a whopping €96M.
ADCT plans to use the funds to advance nothing less than 6 clinical programs in the next 18 months. Two of their candidates, ADCT-301 and ADCT-402, are already in Phase Ia. Both are being tested to treat sub-types of lymphoma and leukemia.
